MAP2K7 and cancer: Since targeted therapies have already been successfully used in several cancers to counteract the enormous survival advantage of cancer cells that establish a supportive TME [30], based on our results, the MEK inhibitor trametinib could be a potent therapeutical option for some MPM patients and would be interesting to be addressed.